For adults with Chronic Idiopathic Constipation (CIC)

Safety profile studied in 2530 adult and elderly patients with CIC

Up and down arrows

Motegrity Safety and Tolerability

The safety and tolerability profile of Motegrity was studied in 2530 patients (Motegrity 2 mg once-daily [N=1251], placebo [N=1279]) with CIC across 6 double-blind, placebo-controlled clinical trials of 12 to 24 weeks duration. Overall, most patients were female (76%) and Caucasian (76%), with a mean age of 47 years (range 17 to 95).1

Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting Motegrity. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for new onset or worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if they experience any of these symptoms.1

No overall differences in safety and effectiveness were observed between elderly and younger patients. Adjust the dosage in elderly patients based on renal function. Avoid Motegrity in patients with end-stage renal disease requiring dialysis.1

Common adverse reactions* reported in patients receiving Motegrity 2 mg or placebo1

Results from double-blind, placebo-controlled trials of CIC of at least 12 weeks duration

Adverse Reaction

Motegrity 2 mg once daily

(N=1251†)

placebo

(N=1279)
Headache 19% 9%
Abdominal Pain‡ 16% 11%
Nausea 14% 7%
Diarrhea 13% 5%
Abdominal Distension 5% 4%
Dizziness 4% 2%
Vomiting 3% 2%
Flatulence 3% 2%
Fatigue 2% 1%

*Reported in ≥‍2% of patients receiving Motegrity and a rate higher than patients receiving placebo. 
†Includes 93 patients who started on Motegrity 1 mg and increased to Motegrity 2 mg. 
‡Includes abdominal pain, upper abdominal pain, lower abdominal pain, abdominal tenderness, abdominal discomfort, and epigastric discomfort.

Less common adverse reactions reported in <2% of patients receiving Motegrity 2 mg once daily included: abnormal GI sounds, decreased appetite, migraine and pollakiuria.

If reported within the first week of treatment, adverse events of diarrhea or headache typically resolved within a few days.1

The majority of patients who reported diarrhea did so in the first week of treatment (n=110/157), and the majority who reported headache did so in the first two days of treatment (n=157/237). For these patients, symptoms typically resolved within a few days (n=80/110 for diarrhea; n=102/157 for headache).1

Severe diarrhea was reported in 1.8% of patients treated with Motegrity 2 mg compared to 1% of patients in the placebo group, and had a similar onset and duration as diarrhea overall.1

Overall, discontinuation due to adverse events was low (5% Motegrity 2 mg once daily, 3% placebo).1

Interested in receiving samples of Motegrity?

Your patients can benefit from a trial. Order a 7-day sample to get started.

package
Bitmap cropped
Request Samples

Cardiovascular Safety Analysis

Cardiovascular safety of Motegrity was evaluated in a MACE analysis of the double-blind, placebo-controlled and open-label studies, as well as in a retrospective observational study which demonstrated no increase in the risk of MACE with Motegrity relative to polyethylene glycol (PEG).1

MACE=Major Adverse Cardiovascular Events, which were defined as: cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.1

§2X max recommended dose of 2 mg. PEG=polyethylene glycol 3350

Bottle icon

Request Samples

Interested in receiving
samples of Motegrity?

Request samples
Map icon

Formulary Coverage

Wondering which plans in your area cover Motegrity? See our patient access coverage tool to find out more.

Patient access coverage tool

IMPORTANT SAFETY INFORMATION

Expand Collapse

Please expand for Indication and Important Safety Information.

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn's disease, ulcerative colitis, and toxic megacolon/megarectum

Warnings and Precautions

Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting Motegrity. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for new onset or worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if they experience any of these symptoms.

Adverse Reactions

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.

Use in Specific Populations

  • Lactation: Motegrity is present in breast milk. Consider risks and benefits of breastfeeding
  • Pediatric: Safety and effectiveness in pediatric patients have not been established
  • Renal Impairment: A decreased dosage is recommended in patients with severe renal impairment. Avoid Motegrity in patients with end-stage renal disease requiring dialysis

INDICATION

Motegrity® (prucalopride) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Please click here for full Prescribing Information.

Reference:

1. Motegrity (prucalopride) Prescribing Information. Lexington, MA: Takeda Pharmaceuticals America, Inc.